Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis

Purpose: The IMpassion130 trial demonstrated the efficacy of adding atezolizumab to paclitaxel for advanced or metastatic triple-negative breast cancer (TNBC). The current study evaluated the cost-effectiveness of adding atezolizumab to nab-paclitaxel for TNBC from the perspective of Chinese health...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Xiaoyan Liu, Yitian Lang, Yahui Liao, Yizhun Zhu
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2021-10-01
סדרה:	Frontiers in Public Health
נושאים:	atezolizumab cost-effectiveness partitioned survival model triple-negative breast cancer the perspective of China
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fpubh.2021.756899/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!